

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found		<p>RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included.</p> <p>RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract.</p> <p>RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.</p>	<p>Line 2-3 title: “...a Registry Study of 529 Conversions.”</p> <p>Line 19-21: “Data of...was used.”</p> <p>NA</p>
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	<p>Line 39-41: Nevertheless, conversion...tibial side.”</p> <p>Line 46-48: “Moreover, Microplasty...Micro plasty surgery.”</p> <p>Line 49-50:”Hence,</p>		

			this...to TKR.”		
Objectives	3	State specific objectives, including any prespecified hypotheses	Line 50-52: “Therefore, we...2 groups.”		
Methods					
Study Design	4	Present key elements of study design early in the paper	Line 66-67: “This retrospective...primary procedures.”		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Line 55-59: “This retrospective...primary procedures.” Line 62-74: “Data of...subsequent re-revision.”		

Participants	6	<p><i>(a) Cohort study-</i> Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</p> <p><i>Case-control study-</i> Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</p> <p><i>Cross-sectional study-</i> Give the eligibility criteria, and the sources and methods of selection of participants</p> <p><i>(b) Cohort study-</i> For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study-</i> For matched studies, give matching criteria and the number of controls per case</p>		<p>RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	<p>Line 62-74: “Data of...subsequent re-revision.”</p> <p>NA</p> <p>NA</p>
Variables	7	<p>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.</p>		<p>RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an</p>	<p>Line 81-82: “The primary...to TKR.”</p> <p>Line 84-87:</p>

				explanation should be provided.	“None of...re-revision rates).”
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Line 62-74: “Data of...subsequent re-revision.” Line 84-87: “None of...re-revision rates).” Line 92-93: “Follow-up period...any reason”.		

Bias	9	Describe any efforts to address potential sources of bias	Line 84-87: “None of...re-revision rates).”		
Study size	10	Explain how the study size was arrived at	Line 62-63: “Data of...and 2019”.		
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	Line 70-72: “To investigate... ≥15mm (‘thick’).”		

Statistical methods	12	<p>(a) Describe all statistical methods, including those used to control for confounding</p> <p>(b) Describe any methods used to examine subgroups and interactions</p> <p>(c) Explain how missing data were addressed</p> <p>(d) <i>Cohort study</i>- If applicable, explain how loss to follow-up was addressed</p> <p><i>Case-control study</i>- If applicable, explain how matching of cases and controls was addressed</p> <p><i>Cross-sectional study</i>- If applicable, describe analytical methods taking account of sampling strategy</p> <p>(e) Describe any sensitivity analyses</p>	<p>a) Line 84-87: “None of...re-revision rates).”</p> <p>b) Line 87-91: “The difference...exact test”.</p> <p>Line 94-97: “Kaplan-Meier analyses...for re-revision”.</p> <p>c) Line 75-80: “PKRs were...component use”.</p> <p>d) Line 92-94: “Follow-up period...any reason.”</p>		
Data access and cleaning methods		..		RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.	<p>Line 58-59: “All data...primary procedures.”</p> <p>Line 75-80:</p>

					“PKRs were...component use”.
--	--	--	--	--	------------------------------

				RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	
Linkage		..		RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	NA

Results

Participants	13	(a) Report the numbers of individuals at each stage of the study (<i>e.g.</i> , numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram		RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Line 114-118:”5 patients... (Table 1)”.
--------------	----	--	--	--	---

Descriptive data	14	<p>(a) Give characteristics of study participants (<i>e.g.</i>, demographic, clinical, social) and information on exposures and potential confounders</p> <p>(b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i>- summarise follow-up time (<i>e.g.</i>, average and total amount)</p>	<p>Line 118-121: “Cementless fixation...[3-5mm]).</p> <p>Line 341: “Table 1”</p>		
Outcome data	15	<p><i>Cohort study</i>- Report numbers of outcome events or summary measures over time</p> <p><i>Case-control study</i>- Report numbers in each exposure</p>	<p>Line 123-147: ”There was...tibial components.”</p>		

		<p>category, or summary measures of exposure</p> <p><i>Cross-sectional study</i>- Report numbers of outcome events or summary measures</p>			
--	--	--	--	--	--

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Line 123-147: "There was...tibial components."		
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	Line 128-131: "The mean...p=0.3)."		
Discussion					
Key results	18	Summarise key results with reference to study objectives	Line 149-153: "We assessed...implanted PKRs."		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias		RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Line 191-217: "Our study...further study."

Interpretation	20	Give a cautious overall interpretation of results considering objectives,	Line 220-223: “We showed...instrumented PKRs.”		
		limitations, multiplicity of analyses, results from similar studies, and other relevant evidence			
Generalisability	21	Discuss the generalisability (external validity) of the study results	Line 220-223: “We showed...instrumented PKRs.”		
Other Information					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Line 106-110: “Since the...submitted article”.		
Accessibility of protocol, raw data, and programming code		..		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	Line 226-230: “SJvL, LNvS...data analyses”.

*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.